Pregabalin Capsule 150 mg
Pregabalin 150mg
Hard capsule · Prescription medication
KMS Pharma Co., Ltd.
MFDS item code 201908674 · Approved 2019.12.27
This product's status changed to Expired on 2024.12.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in epilepsy patients, applicable whether secondary generalized symptoms are present or not. Additionally, it is effective in alleviating symptoms of fibromyalgia. It aids in managing various neurological disorders and pain, improving the patient's quality of life.
This medication is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosage regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal ideation or behavior, so any changes in mood or unusual behavior during treatment should be reported to a doctor immediately. Do not use if you are allergic to any components in this medication or if you have certain genetic issues such as lactose intolerance. Diabetic patients should be cautious as weight gain during treatment may require adjustment of blood sugar control medications. If symptoms of angioedema occur, such as swelling of the face or around the mouth, discontinue use immediately and consult a healthcare professional. Elderly patients may experience dizziness, drowsiness, or confusion when taking this medication, so care should be taken especially when starting treatment. If vision becomes blurry or changes in eyesight occur, symptoms may improve upon discontinuation of the medication, so monitoring for abnormal symptoms is advised. Abrupt discontinuation or long-term use may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety; consult with a healthcare professional for dosage adjustments. There is a risk of drug abuse, so individuals with a history of mental health issues or substance abuse should consult prior to use. Patients with impaired kidney function may require dose adjustment. Patients with severe heart disease need to take caution when using this medication and should follow healthcare provider instructions. Co-administration with opioid analgesics may increase the risk of central nervous system depression, so caution is warranted. This medication may cause serious side effects like respiratory depression, so patients with respiratory or kidney disorders should discuss this with their healthcare provider. During early pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant must consult with a doctor before use and should employ effective contraceptive methods. Breastfeeding women should discuss with healthcare providers about either stopping breastfeeding or discontinuing the medication, as this drug can be passed into breast milk and affect the infant. This medication may cause dizziness and drowsiness. Caution is advised when driving or operating machinery, and it is best to avoid hazardous activities until symptoms have completely resolved. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and immediate medical attention is required. Keep this medication out of reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to protect it from air and moisture, ideally at room temperature between 15 to 30 degrees Celsius. This will help maintain the effectiveness of the drug over time.
A hard capsule with a white body and a white powder inside.
Domestic - 30 capsules/bottle, Domestic - 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
KMS Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.